According to results from lab studies, an antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology preserves neutralising activity against the developing BA.2 type of the Omicron coronavirus variant.
The business stated it would reveal preprint data in the coming week, followed by live viral data.
According to the business, the 500 mg dose of sotrovimab is sufficient to maintain action against the BA.2 variation, which is in line with all other variants of concern and interest, based on pseudovirus and substantial pharmacokinetic data.
Sotrovimab is one of the few COVID-19 therapies that has been demonstrated to act against the fast-spreading Omicron form, which has sparked interest. In 2021, it was one of GSK’s best-selling products.